Tag Archives: severe aortic stenosis

Post-dilatación de válvulas autoexpandibles

Self-Expanding Valve in Extreme Surgical Risk After 5 Years

Self-Expanding Valve in Extreme Surgical Risk After 5 Years

Patients with aortic stenosis and extreme surgical risk have extremely high mortality due to known comorbidities. The short-term benefit of transcatheter aortic valve replacement (TAVR) with self-expanding valve is clear, and it warrants the procedure in this challenging population. While elderly patients with comorbidities who are at extreme surgical risk might be eligible for TAVR,

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

SCOPE I: Acurate NEO vs Sapien 3, no non-inferiority at one year?

The randomized controlled study SCOPE 1 failed to show significant differences at one year between the self-expandable Acurate neo and the balloon expandable Sapien 3.  The SCOPE 1 (Safety and Efficacy of the Symetis ACURATE neo/TF Compared to the Edwards SAPIEN 3 Bioprosthesis) compared the balloon expandable Sapien 3 (which has probably more data) against

El aumento de la experiencia de los operadores mejora los resultados en el TAVI

TAVR in Low-Risk Patients: Though still Superior, with Diminished Advantage after 2 Years.

At two-year followup, primary end point continued to be significantly lower with Sapien 3 vs. conventional surgery, but the initial difference in death and stroke in favor of TAVR started to shrink.  In addition, there was higher risk of valve thrombosis in TAVR patients.  The PARTNER 3 (Safety and Effectiveness of the SAPIEN 3 Transcatheter

Death, Stroke, and Hospitalization while Waiting for TAVR

The consequences of deferring transcatheter aortic valve replacement (TAVR) procedures because of the COVID 19 pandemic are piling up. Untreated severe aortic stenosis patients who had been scheduled for TAVR are seeing increased risk of all events, even mortality.  According to recent studies published in JAMA, deferring TAVR in patients with symptomatic aortic stenosis is

TAVI bajo riesgo

TAVR as Anti-Inflammatory? An effect few imagined

We never saw it coming, such a pleiotropic effect: who would have though a mechanical device could have such a systemic anti-inflammatory effect? Transcatheter aortic valve replacement (TAVR) does in fact have it.  The shear stress aortic stenosis produces activates multiple inflammatory responses mediated by monocytes. This study identified the most important mechanoreceptor, involved in

Válvula Bicúspide

Good Evolution of Bicuspid Valves with EVOLUTE or EVOLUTE PRO

Courtesy of Dr. Carlos Fava. TAVR has matured over time and has advanced onto low risk patients, but one of its greatest challenges continues to be bicuspid valve patients. These represent between 1% and 2% of the population and over 20% of young adults requiring surgical valve replacement (SAVR).  The study looked at 27,086 patients

Enfermedades malignas y estenosis aórtica ¿Se justifica el TAVI?

Malignancies and Aortic Stenosis: Is TAVR Warranted?

This meta-analysis tells us that patients with active malignancies and severe aortic stenosis have a good evolution after transcatheter aortic valve replacement (TAVR), except for a higher rate of pacemaker implantation in the general population. These patients must not be limited to respite care only, at least as far as aortic stenosis is concerned. Short-term

¿Se debe tener en cuenta el género para revascularizar el tronco?

Myocardial Fibrosis in Severe Aortic Stenosis: A Matter of Sex?

Courtesy of Dr. Carlos Fava. Aortic valve calcification and its resulting stenosis leads to changes in left ventricle hemodynamics, producing diffuse ischemia followed by inflammation, increased extracellular matrix, necrosis, and later, diffuse fibrosis.  At present, with magnetic resonance imaging (MRI) we can analyze ventricular architecture and its function by detecting fibrosis (LGE) and its volume

Recomendaciones de la ACC con el nuevo coronavirus

Procedural Rescheduling Criteria in the Pandemic Era

Patients with structural heart disease are at higher risk in the face of the new coronavirus infection due to both advanced age and numerous comorbidities. All variables must be taken into account when deciding whether a patient can wait (so as to minimize the risk of exposure to the virus) or their pathology must be

Virtual ACC 2020 | First Results of Evolut in Low-Risk Bicuspid Valves

The initial results of this study presented “virtually” at the American College of Cardiology (ACC) 2020 Scientific Session suggest that patients with severe bicuspid aortic stenosis can be treated with self-expandable valve Evolut. This is a small study presenting its 30-day outcomes. There is still a long way to go. The rate of all-cause mortality